Use of raloxifene among women with a history of breast cancer

Habel, Laurel A.; Pressman, Alice; Ettinger, Bruce; Sidney, Stephen; Suh-Burgmann, Elizabeth; Fehrenbacher, Louis; Quesenberry, Charles P.

doi:10.1007/s10549-005-9069-8

Cited by 4 publications

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The use of raloxifene is not a prevalent practice in patients following a diagnosis of breast cancer. 10 Still, there could be patient populations where its anti-osteoporotic effects may be an attractive feature for its use, in particular when other anti-estrogen modulators and aromatase inhibitors are not well tolerated. In addition, raloxifene may be an experimental treatment option for recurrence risk prevention, especially in patients with a history of osteoporosis or osteopenia.…”

Section: Discussionmentioning

confidence: 99%

Anti-Estrogen Withdrawal Effect With Raloxifene? A Case Report

Lemmo¹

2016

Integr Cancer Ther

View full text Add to dashboard Cite

A 66-year-old patient presented with acute recurrent metastatic estrogen and progesterone receptor–positive, Her-2/neu-negative breast cancer, bone lesions (lumbar spine, pelvis), pulmonary nodules, hepatic metastasis, elevated cancer antigen 15 and liver enzymes, dyspepsia, and diarrhea. The patient had been taking raloxifene for approximately 8 years. After discontinuation, clinical parameters and symptoms improved rapidly without oncological therapy or other forms of treatment. Three months after raloxifene discontinuation, capecitabine was initiated by the treating oncologist who deemed an anti-estrogen withdrawal effect (AEWE) implausible. However, the lasting regression was more indicative of a raloxifene rebound effect than chemotherapy or other interventions. Today, the patient is asymptomatic with a good performance status. Hepatic metastatic regression has been confirmed, without any oncological treatment administered in the past 16 months and approximately 23 months following the withdrawal of raloxifene. This case highlights the need to screen breast cancer patients for the possibility of an AEWE if they are using raloxifene and possibly similar selective estrogen receptor modulators (SERMs) which includes tamoxifen, when diagnosed with advanced breast cancer, especially in the recurrent disease setting.

show abstract

Section: Discussionmentioning

confidence: 99%

Anti-Estrogen Withdrawal Effect With Raloxifene? A Case Report

Lemmo¹

2016

Integr Cancer Ther

View full text Add to dashboard Cite

show abstract

Current awareness: Pharmacoepidemiology and drug safety

2006

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 20 sections: 1 Books, Reviews & Symposia; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Teratogens/fetal exposure; 20 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.

show abstract

Antitumorigenic Effects of Tamoxifen, Raloxifene and the Combination on the Development of Breast Tumors Induced by Mouse Mammary Carcinoma Cells in Balb/c-J Female Mice

Goel

Majumdar²

2009

Journal of Chemotherapy

View full text Add to dashboard Cite

The antitumorigenic efficacy of tamoxifen, raloxifene, and their combination was evaluated on 4t1 estrogen-positive murine mammary carcinoma cells by determining their ability in breast tumor development in balb/c-J female mice. Each mouse received intraperitoneally 0.1 ml of pbS solvent containing no drug, 12 mg (0.6 mg/kg) of tamoxifen, 36 mg (1.8 mg/kg) of raloxifene, or the combination of the two drugs (12 mg tamoxifen + 36 mg raloxifene) at 48-hour intervals for 35 days. Drug concentrations used were equivalent to human doses. within the study period of 35 days, tamoxifen demonstrated the greatest effectiveness, as it allowed "progression-free survival," increased mouse life span by an average of 6 days, had the greatest number of survivors (90.9%), and those with the smallest spleen weight and volume. Raloxifene and combination groups, compared to the drug-untreated mice, did not significantly lengthen the life span or survivability, produced grossly enlarged spleens, and mice exhibited maladies such as leg paralysis and acute lethargy.

show abstract

Use of raloxifene among women with a history of breast cancer

Abstract: In this setting, raloxifene use among women with a history of breast cancer is related to stage at diagnosis and bone mineral density and is rare among women who have completed a 5-year course of adjuvant tamoxifen.

Cited by 4 publications

References 17 publications

Anti-Estrogen Withdrawal Effect With Raloxifene? A Case Report

Anti-Estrogen Withdrawal Effect With Raloxifene? A Case Report

Current awareness: Pharmacoepidemiology and drug safety

Antitumorigenic Effects of Tamoxifen, Raloxifene and the Combination on the Development of Breast Tumors Induced by Mouse Mammary Carcinoma Cells in Balb/c-J Female Mice

Contact Info

Product

Resources

About